An open-label, dose-escalation, phase I study of AVE9633 administered as an intravenous infusion to patients with relapsed or refractory CD33-positive acute myeloid leukaemia
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2007
At a glance
- Drugs AVE 9633 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 10 Dec 2007 Interim results were reported at ASH in December 2007.
- 19 Jan 2007 Interim results have been reported.
- 19 Jan 2007 Status change